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Or. FR. 
By letter of 13 February 1990 the Council consulted the European Parliament, 
pursuant to Article 100a of the EEC Treaty, on the Commission proposal for a 
Council directive on the wholesale distribution of medicinal products for 
human use. 
At the sitting of 12 March 1990 the President of Parliament announced that he 
had referred this proposal to the Committee on the Environment, Public Health 
and Consumer Protection as the committee responsible and to the Committee on 
Economic and Monetary Affairs and Industrial Policy and the Committee on 
Budgets for their opinions. 
At its meeting of 23 March 1990 the Committee on the Environment, Public 
Health and Consumer Protection appointed Mrs Ceci rapporteur. 
At its meetings of 9 November and 18 December 1990 and of 31 January and 
25 April 1991 it considered the Commission proposal and draft report. 
At the last meeting it adopted the draft legislative resolution by 29 votes to 
2 with 2 abstentions. 
The following were present for the vote: Collins, Chairman; Schleicher, 
vice-chairman; Ceci, rapporteur; Alavanos, Alber, Amendola, Banotti, Bertens, 
Bj0rnvig, Bombard, Bowe, Canavarro, Chanterie, Diez de Rivera lcaza, Di Rupo, 
Florenz, Green, Guidolin, Hadjigeorgiou (for Douste-Blazy), Jensen, Kuhn, 
llorca Vilaplana, Monnier-Besombes, Oomen-Ruijten, Partsch, Pollack, 
Roth-Behrendt, Schwartzenberg, Simmonds, llewellyn Smith, Valverde lopez, 
Veil, Vernier, Vertemati and Vittinghoff. 
The opinions of the Committee on Economic and Monetary Affairs and Industrial 
Policy and the Committee on Budgets are attached. 
The report was tabled on 30 April 1991. 
The deadline for tabling amendments will appear on the draft agenda for the 
part-session at which the report is to be considered. 
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A 
Commission proposal for a Council directive 
on the wholesale distribution of medicinal products for human use 
Commission text1 Amendments 
(Amendment No. 1) 
First recital a (new) 
Whereas, according to Art i c 1 e 1 OOa, 
the completion of the internal 
market must be based on the highest 
possible level of environmental, 
public health and consumer 
protection; 
(Amendment No. 2) 
Second recital 
Whereas the wholesale distribution 
of medicinal products for human use 
is at present subject to different 
prov1s1ons in the various Member 
States; whereas many operations 
involving the wholesale distribution 
of medicinal products may cover 
simultaneously several Member 
States; 
Whereas the wholesale distribution 
of medicinal products for human use 
is at present subject to different 
prov1s1ons in the various Member 
States; whereas many operations 
involving the wholesale distribution 
of medicinal products cover and will 
increasingly cover simultaneously 
several Member,States; 
(Amendment No. 3) 
Third recital 
Whereas it is necessary to exercise 
control over the entire chain of 
distribution of medicinal products, 
from their manufacture or import 
into the Community through to supply 
to the public, so as to guarantee 
that such products are stored, 
transported and handled in suitable 
conditions; whereas the requirements 
which must be adopted for this 
purpose will considerably facilitate 
the withdrawal of defective products 
from the market and allow more 
effective efforts against 
counterfeit products; 
Whereas it is necessary to exercise 
control over the entire chain of 
distribution of medicinal products, 
from their manufacture or import 
into the Community through to supply 
to the pub 1 i c, so as to guarantee 
that such products are stored, 
transported and subject to all the 
stages in the distribution process, 
with a view to effective efforts 
against counterfeit products and to 
facilitating the prompt withdrawal 
of defective products from the 
market; 
1 For full text see COM(89) 607 final - OJ No. C 58, 8.3.1990, p. 16 
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Commission text Amendments 
(Amendment No. 4) 
Fourth recital 
Whereas any person i nvo 1 ved in the 
wholesale distribution of medicinal 
products should be in possession of 
a special authorization; whereas 
pharmacists and persons authorized 
to supply medicinal products 
directly to the public, and who 
confine themselves to this activity, 
~houl d_ be_~~emp! ___ f_l'_'Q_"!__obt~JBj__119_ thi ~ 
~l!~!'l~rizalion; where~s il _i_s .. ~1~_aY-S 
n~c~_~sary in order to c_on~_ro] __ !b~ 
~ompl~~~- ---~~J!l .... Qf__d_t_stri bu_!; ion _of 
medicinal products, that pharmacists 
and persons authorized to deliver 
medicinal products to the public 
keep records showin~ entry 
lra!l~a~_q_Qns_; 
Whereas any person i nvo 1 ved in the 
wholesale distribution of medicinal 
products should be in possession of 
a specific authorization; whereas 
the definition of distribution does 
not cover dividing up, packaging and 
presentation operations referred to 
in Article 16 of Directive __ l~L~_1_9 
and in the amendments thereto or 
----·- - ---- ·-------- -·--· 
f?per:ali_p_!l~ _ _]_i_'!_ked lo direct ·.upply 
t_9_ th~. pu~l_ic; 
(Amendment No. 5) 
Fourth recital a (new) 
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Whereas it is necessary to lay down 
uniform rules applicable throughout 
the Community with a view to 
establishing the conditions for 
obtaining authorizationL 
arrangements in connection with 
transport, personnel and premises, 
and the procedures for the checks to 
be carried out by the Member States; 
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Commission text Amendments 
(Amendment No. 6) 
Article 1(2) 
2. For the purposes of this 
Directive, the definition of 
"medicinal products" set out in 
Article I of Council Directive 
65/65/EEC 1 shall apply. In addition 
"wholesale distribution of medicinal 
products" shall mean all activities 
consisting of procuring, holding, 
supplying, importing or exporting 
medicinal products. 
2. For 
directive 
the purposes of this 
the definition of 
medicinal products set out in Annex 
I of Council Directive 65/65/EEC 1 
shall apply. In addition 
'wholesale distribution of medicinal 
products' shall mean all activities 
consisting of procuring, holding, 
supplying to persons other than the 
final consumer, importing or 
exporting medicinal products. The 
import of medicinal products from 
third countries corresponds to 
marketing and shall therefore be 
deemed to be equivalent to the 
activities of manufacturers. 
(Amendment No. 7) 
Article 1(2a)(new) 
DOC_EN\RR\109020 
2a. For the purposes of this 
directive 'public service 
obligations' shall include the 
=o~b~l~i~g~a~t~i=o~n ___ f~o~r ___ w~h~o~l~e~s~a~l~e~r~s--~to 
guarantee a constant range of 
medicinal products to meet the needs 
of a geographically determined 
territory and to ensure the supply 
at very short notice of the products 
requested throughout the territor~ 
.:!!! _ _g_~ ~~ 1.Q_Il_._ 
(Amendment No. 8) 
Article 1(3)(new) 
A wholesale distributor of medicinal 
products shall be responsible for 
ensuring a full range of proprietary 
medicinal products and for m~~1~9 
them availabk_ __ J>t:~"!PU..Y_ on lhe 
!_~_r _'=. L t_Q_!:_}' ____ f.<>_!"_ w h _ 1 c h h e 1 5 
responsible. 
(Amendment No. 9) 
Article 3, title (new) 
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Persons to be granted authorization 
PE 145.360/fin. 
Or. FR. 
Co11111ission text Amendments 
(Amendment No. 10) 
Article 3(3) 
3. The ~ossession of an 
authorization to carr~ out the 
activit~ of a wholesaler of 
medicinal ~roducts shall not 
dis~ense from the obligation to 
~ossess a manufacturing 
authorization or an authorization 
for im~ortation from third countries 
in accordance with Article 16 of 
Council Directive 75/319/EEC~. and 
to corn~ 1 y with the conditions set 
out in that res~ect, even when the 
manufacturing activity is secondary. 
3. A manufacturer in ~ossess ion of 
an authorization in accordance with 
Article 16 of Directive 75/319 who 
~roposes to distribute a ~roprietary 
medicinal ~roduct directly may 
a~ply, to the relevant health 
authorities in the Member State in 
which he proposes to engage in 
distribution activities, and obtain 
an authorization restricted to that 
~ r o p r i e t a r y p r o d u c t . 
Manufacturers/importers wishing to 
sup~ly their ~roducts to another 
holder of such authorization and/or 
a number of distributors must have 
authorization to engage in wholesale 
trade in their own ~roducts. 
(Amendment No. 11) 
Article 5, title (new) 
Requirements for granting the 
authorization 
(Amendment No. 12) 
Article 5(a) 
(a) they must have suitable and 
adequate premises, such as to 
ensure good conservation of the 
medicinal products warehoused; 
(a) they must have suitable and 
adequate premises, such as to 
ensure good conditions for 
conservation and handling, 
appropriate to the nature of the 
medicinal products warehoused as 
well as suitable arrangements 
for the ~ro~er handling and 
transport of medicinal ~roducts; 
(Amendment No. 13) 
Article 5(aa) (new) 
2 OJ No. L 147, 9.6.1975, p. 13 
DOC_EN\RR\109020 - 7 -
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stringent laboratory hygiene 
and safety rules are a~plied; 
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Commission text Amendments 
(Amendment No. 14} 
Article 5(b} 
(b) they must have a qualified 
personnel meeting the 
conditions provided for by the 
legislation of the Member State 
concerned; 
(b) They must have qualified 
personnel working under the 
res pons i bil ity of a pharmacist, 
meeting the conditions provided 
for by the legislation of the 
Member State concerned; 
(Amendment No. 15} 
Article 5(c} 
(c) they must undertake to ful fi 1 
the obligations incumbent on 
them under the terms of 
Article 6. 
(c) they must undertake to comply 
with sound distribution 
practices and to establish that 
they have the requisite means at 
their disposal to apply them in 
practice. 
(Amendment No. 16} 
Article 5(ca}(new} 
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(ea} They must guarantee the 
presence of a pharmacist with the 
following responsibilities: 
1. The administration and 
supervision of the technical 
services responsible for general 
hygiene in the pharmacies 
2. Quality control and analysis of 
unpackaged products to ensure 
that they meet the re qui red 
standards 
3. Keeping and checking laboratory 
analysis report files 
4. Stocktaking, ensuring suitable 
storage conditions in particular 
for narcotic and toxic 
substances in general and 
keeping a detailed inventory of 
the arri va 1 and remova 1 of 
stocks 
5. Checking final dates for use 
6. The withdrawal of products if 
necessary. 
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Commission text Amendments 
(Amendment No. 17) 
Article 6, title (new) 
Obligations incumbent on wholesale 
distributors of medicinal products 
(Amendment No. 18) 
Article 6, first phrase 
Holders of the authorization 
referred to in Article 3(1) shall be 
required: 
Holders of the authorization 
referred to in Article 3(1) shall be 
obliged: 
(Amendment No. 19) 
Article 6(a) 
(a) to make the premises referred 
to in Article S(a) accessible 
at all times to the persons 
responsible for inspecting 
them; 
(a) to make the premises, facilities 
and procedures used accessible 
at all times to the persons from 
the competent authorities 
responsible for inspecting them. 
(Amendment No. 20) 
Article 6(b) 
(b) to obtain medicinal products 
only from persons who are 
themselves in possession of the 
authorization referred to in 
Article 3( 1) or who are exempt 
from o b t a i n i n g t h 1 s 
authorization under the terms 
of Article 3(2); 
(b) to obtain medicinal products 
only from persons who hold an 
authorization as referred to in 
Article 16 et seq of Dir~ct_i~_E'!_ 
_?_5/319/_E_J:C, or who are 
themselves in possession of lhe 
author1 zat ion referred to in 
Article 3(1} or who are exempt 
from obtaining this 
authorization under the terms 
of Article 3(2); 
(Amendment No. 21) 
Article 6(c) 
(c) to supply medicinal products 
on 1 y to persons who are 
themselves in possession of the 
authorization referred to in 
Article 3(1) or who are exempt 
from obtaining this 
authorization under the terms 
of Article 3(2); 
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way with the medicinal products 
distributed by them; 
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Commission text Amendments 
(Amendment No. 22} 
Article 6(d} 
(d) to have an emergency plan which 
allows participation in any 
action of wi thdrawa 1 from the 
market ordered by the competent 
~uthorities or initiated by the 
manufacturer of the medic i na 1 
product concerned; 
(d) to acce2t an emergency plan 
which allows participation in 
any action of withdrawal from 
the market ordered by the 
competent authorities of the 
Member State or initiated by the 
manufacturer/importer of the 
medicinal product concerned; 
The Commission shall entrust the 
European Community organization set 
up under Council Regulation No. 
(EEC} with the task of coordinating 
at Community level all emergency 
plans for the withdrawal of a 
medic i na 1 2roduct from the market. 
Pending the setting-up of this body, 
a 1 1 de a 1 er s w i t h i n form at i on 
concerning the medicinal product 
being withdrawn from the market 
shall immediately inform their 
sup2liers and customers. In 
addition all wholesalers and 
wholesale distributors shall check 
their stocks for the presence of the 
medicinal 2roduct and prevent it 
from entering the market. 
(Amendment No. 23} 
Article 6(da}(new} 
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to dispatch products requested 
within 12 hours of receiving a 
request, and within 24 hours 
where isolated areas are 
involved, and at all times to 
organize emergency deliveries 
in the event of a disaster; 
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Commission text Amendments 
(Amendment No. 24) 
Article 6(e) 
(e) to keep deta i 1 ed records, 
possibly computerized, stating 
for each transaction in 
medicinal products received or 
dispatched, the following 
information: 
- date, 
- name of the medicinal product, 
- production batch number, 
-quantity received or supplied, 
- name and address of the 
supplier or consignee; 
when the delivery is destined for 
a retailer, the production batch 
number is not required; 
(e) to keep detailed computerized 
records stating for each 
transaction in medicinal 
products received or dispatched, 
the following information: 
- date, 
- name of the medicinal product, 
- production batch number, 
- quantity received and 
supplied, 
- name and address of the 
supplier and consignee; 
when the delivery is destined for 
a reta i 1 er, the production batch 
number is not required; 
(Amendment No. 25) 
Article 6(ga)(new) 
DOC_EN\RR\109020 
member of staff referred to in 
Article 5(b) with the 
supervision and checking of 
the operations referred to in 
paragraphs (d), (e) and (g) of 
this Article; 
(Amendment No. 26) 
Article 6(gb)(new) 
(gb) to have suitable facilities 
for the stroage and transport 
of products requiring special 
arrangements in respect of 
their conservation, human 
safety or environmental 
protection; 
(Amendment No. 27) 
Article 6(gc)(new) 
- 11 -
(gc) to provide adequate guarantees 
for the continuation of the 
cold chain in the transport 
and storage of medicinal 
products which need to be kept 
at certain termperatures; 
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Commission text 
DOC_EN\RR\109020 
Amendments 
(Amendment No. 28) 
Article 6(gd)(new) 
(gd) not to supply products that 
are physically damaged, 
damaged as a result of 
variations in temperature or 
humid i!L__or __ ~_'?J!tami f!(lJ:.ed ,_ or 
products reachi!:!.g_~-~-~nd __ ~f 
their shelf 11f~ 
(Amendment No. 29) 
Article 6(ge)(new) 
(ge) to store damaged products 
separate 1 y and to dispose of 
them only as directed __ b_y_ __ t_he 
competent authorities; 
(Amendment No. 30) 
Article 6(gf)(new) 
(gf) to dispatch products in such a 
way that they can be always 
identified; 
(Amendment No. 31) 
Article 6(gg) (new) 
(gg) not to accept for 
redistribution products that 
have been returned if: 
they are not in their original, 
sea 1 ed and unopened packaging and 
are not in good condition; 
(Amendment No. 32) 
Article 7, title (new) 
- 12 -
Qualifications and duties of 
personnel in charge 
PE 145.360/fin. 
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Co11111ission text Amendments 
(Amendment No. 33} 
Article 7(1a}(new} 
la. The public service obligations 
imposed by certain Member States on 
wholesalers established in their 
territories shall not be affected by 
this directive. 
(Amendment No. 34} 
Article 8 
1. All pharmacists, as well as all 
persons authorized to supply 
medicinal products to the public, 
shall be required to keep accurate 
records, possibly computerized, 
giving the following details at 
least for each transaction of 
medicinal products received: 
- date, 
- name and pharmaceutical form of 
the medicinal product, 
- quantity received, 
- name and address of the supplier. 
2. The records referred to in 
paragraph 1 shall be kept 
available to the competent 
authorities, for inspection 
purposes, for a period of three 
years. 
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1. All pharmacists, as well as all 
persons authorized to supply 
medicinal products to the public, 
shall be required to keep accurate 
records, possibly computerized, or a 
file of documents from suppliers, 
giving the following details at 
1 east for each transaction of 
medicinal products received or 
dispatched, such as to enable th'e;;;" 
to participate in any recall action 
which may take place: 
- date, 
- name and pharmaceutical form of 
the medicinal product, 
- quantity received and supplied, 
- name and address of the supplier 
and prescriber, 
2. The records or files of 
documents referred to in 
paragraph 1 shall be kept 
available to the competent 
authorities, for inspection 
purposes, period of three 
years. 
3. If an emergency p 1 an comes into 
effect, the pharmacist shall 
ascertain whether he has batches 
of the product or products 
concerned in stock. 
PE 145.360/fin. 
Or. FR. 
Commission text Amendments 
(Amendment No. 35) 
Article 10 
If appropriate, the Commission shall 
publish guidelines on good 
distribution practices. In that 
case the pharmaceutical committee 
i n s t i t u t e d b y C o u n c i 1 
Decision 75/320/EEC 1 shall be 
consulted. 
1 OJ No. L 47, 9.6.1975, p. 23 
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Within a period of two years from 
the date of adoption of this 
directive, the Commission shall 
publish guidelines on good 
distribution practices. It shall 
update this publication annually. 
It shall consult for this purpose 
the pharmaceutical committee 
instituted by Council Decision 
75/320/EEC. 
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A 
DRAFT LEGISLATIVE RESOLUTION 
(Cooperation procedure: first reading) 
embodying the opinion of the European Parliament on the Commission proposal 
for a Council directive on the wholesale distribution of medicinal products 
for human use 
The European Parliament, 
having regard to the Commission proposal to the Council (COM(89) 607 final 
- SYN 229) 2 , 
having been consulted by the Council pursuant to Article 100a of the 
Treaty (C3-0113/91), 
having regard to the report of the Committee on the Environment, Public 
Health and Consumer Protection and the opinions of the Committee on 
Economic and Monetary Affairs and Industrial Policy and the Committee on 
Budgets (A3- ... / .. ), 
1. Approves the Commission proposal subject to Parliament's amendments and in 
accordance with the vote thereon; 
2. Calls on the Commission to amend its proposal accordingly, pursuant to 
Article 149{3) of the EEC Treaty; 
3. Calls on the Council to incorporate Parliament's amendments in the common 
position that it adopts in accordance with Article 149{2)(a) of the EEC 
Treaty; 
4. Instructs its President to forward this opinion to the Council and 
Commission. 
'I OJ No. C 58, 8.3.1990, p. 16 
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8 
EXPLANATORY STATEMENT 
Distribution is the intermediate stage when a medicinal product reaches the 
retailer from the manufacturer, during which product quality, safety and 
efficacy depend on optimum storage, transport, handling and knowledge of the 
physico-chemical and biological properties of the product concerned. 
In economic terms, the distributive sector has become increasingly important, 
accounting for 8 to 13% of the sector's entire turnover and employing tens of 
thousands; it has been characterized in recent years by a major process of 
concentration, as has manufacturing. 
As regards organizational setup in general, however, there are major 
differences in some Community countries in specific areas. In Spain, for 
example, cooperatives operate in the distributive sector, while, in Belgium, 
there are still small firms operating {39), 10 of which are pharmacists' 
cooperatives and account for 42% of the volume of pharmaceutical products 
distributed in the country. 
Many countries have adopted specific rules, but the position at present is 
uncertain and lacks consistency. In particular: 
not all countries insist on an authorization; 
not all countries have laid down the requirements to be met by the person 
in charge of techn i ea 1 organization {in France, that person must be a 
member of the Pharmacists' Association); 
duties and responsibilities are not clearly defined; 
inspections are not comprehensive and are often not carried out. 
To date, no Community legislation has applied specifically to the distributive 
sector. Inspections of manufacturing and commercial establishments are 
referred to only in Article 26 of Directive 75/3193 ; but this is because of 
the persistent failure to distinguish between manufacturing and imports and 
not because direct action was taken to deal with the specific problem in 
question. 
Community action is all the more necessary, then, since it is precisely the 
area of trade between the Member States and between them and third countries 
which is the source of some of the more worrying distortions on, and damage 
to, the medicinal-products market. 
The fact that there are parallel markets via which a sizeable proportion of 
production is withdrawn from the official distribution chain {manufacturer, 
distributor, retailer), and put through a further intermediate stage 
{manufacturer, distributor in one Member State, distributor in a second 
Member State, retailer), can most certainly be termed a distortion of the 
market. 
3 OJ No. L 147, 9.6.1975 
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What usually happens during this intermediate stage is that products are 
improperly handled in a variety of ways with a view to obtaining an 
authorization to market the product concerned in a second Member State at a 
higher price than in the first Member State. 
The problems in this regard are those of: 
1. Legality; 
2. Fair competition vis-a-vis firms operating in one Member State only; 
3. Consumer safety, since the products are improperly handled in order simply 
to increase their commercial value rather than to enhance their medicinal 
value. 
Furthermore, over the last few years, uncontrolled distribution activities 
have been a factor helping to establish a black market in medicinal products, 
which is a serious and dangerous development; this market exists side by side 
with the market in narcotic substances, albeit less prominent and less 
tangible. The preferred routes are to be found precisely in those areas where 
there are fewer checks; and these include the distribution chain for 
veterinary products. 
The objectives behind the proposal for a directive (COM(89) 607 - SYN 229) 
therefore merit our wholehearted support. 
We take the view, however, that the measures proposed are inadequate in that 
they: 
(a) fail to make the entire distribution chain transparent; 
(b) fail to delimit clearly the duties and responsibilities to be discharged 
at the various manufacturing, distribution and retail levels; 
(c) fail to lay down sound distribution practices for the entire Community. 
The amendments proposed are designed to respond to these points, with a view 
to making the proposal a more fitting and more effective vehicle for realizing 
the objective of a single market while fully taking heed of the safety and 
interests of the consumer including his economic interests. 
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0 P I N I 0 N 
(Rule 120 of the Rules of Procedure) 
of the Committee on Economic and Monetary Affairs and Industrial Policy 
for the Committee on the Environment, Public Health and Consumer Protection 
Draftsman: Mr SISO CRUELLAS 
At its meeting of 27 June 1990, the Committee on Economic and Monetary 
Affairs and Industrial Policy appointed Mr SISO CRUELLAS draftsman. 
At its meetings of 26-28 June, 25 and 27 September and 15-16 October 1990, the 
committee considered the draft opinion. It adopted its conclusions by 20 
votes to none, with one abstention. 
The following took part in the vote: Beumer, chairman; Fuchs, vice-chairman; 
Siso Cruellas, draftsman; Cassidy, Cox, Ernst de la Graete, Herman, lulling, 
Merz, Metten, Pinxten, Rogalla, Speciale, Amaral (for de Donnea), Martinez 
(for Megret), Nielsen (for Visentini), Peter (for Ford), Randzio-Plath (for 
Hoff), Titley (for Seal), Van der Waal (for lataillade) and Navarro (for 
Gallenzi) pursuant to Rule 111(2). 
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I. Proposal for a directive on the wholesale distribution of medicinal 
products for human use 
1. Contents of the proposal 
(a) The present situation 
The distribution systems for pharmaceuticals have hitherto been organized 
along national lines, and cross-frontier distribution systems have been the 
exception. This situation will change in the future; from now on, it will be 
necessary to take account of parallel imports4 , and also of the EC Court of 
Justice ruling that a Member State may not prevent a wholesaler established in 
another Member State from directly supplying pharmacies in its territory. 
This process will be accelerated by the completion of the internal market. 
It is now desirable to regulate 
products in the Community, thus 
national regulations. 
(b) The proposed control measures 
the wholesale distribution of medicinal 
superseding the present multiplicity of 
The objective of the Commission proposals is to ensure, in the context of the 
increasing internationalization of the wholesale distribution system in the 
Community, that medicinal products are stored, transported and handled in 
adequate conditions. The proposed measures also concern the safety of 
supplies and, in particular, the capacity of the distribution system to 
effect, as quickly as possible, the supply of medicinal products and, where 
necessary, their withdrawal from the market. 
To this end, the directive proposes that a specific authorization should be 
issued for wholesale distribution (see Article 3). Such an authorization 
would be issued by the Member State in which the wholesaler's storage premises 
is situated and only on condition that a certain number of minimum 
requirements were met (suitable premises, qualified personnel and 
compatibility of the products distributed). 
Should these conditions not be fulfilled, the Member State would be enabled to 
suspend or revoke the authorization. 
The Commission would also, if appropriate, publish guidelines on good 
distribution practice (see Article 10). 
2. Comments 
The completion of the single market will probably lead to an increase in the 
cross-frontier circulation of pharmaceuticals. The proposal for a directive 
therefore corresponds to a specific need. However, the term 'who 1 esa 1 er' 
should be more precisely defined (cf. Articles 1 and 3). It is also essential 
that the conditions of storage, preservation and handling should be subject to 
the strictest possible rules. In fact, many products are created by advanced 
technologies, and it is vital that they should reach the patient both rapidly 
4 European Court reports: Cases 87 and 88/85, 27 May 1986 
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and undamaged. Further specifications to this end could be added to the text 
(see Articles 5 and 6). 
The same applies to Article 9, which in practice only concerns dispensers 
(pharmacists and hospitals) and not the public. 
It may also be asked whether it is desirable to include rules concerning 
pharmacists in this directive (see Articles 7 and 8), given that they are 
retailers. 
DRAFT AMENDMENTS 
to the proposal for a directive on the wholesale distribution of medicinal 
products for human use 
Commission text 
Amendment No. 1 
Article 1(2) 
2. For the purposes of this 2. For the purposes of lhi s 
Directive, the definition of 
'medicinal product' set out in 
Article 1 of Council Directive 
65/65/EEC1 shall apply. In 
addition 'wholesale distribution 
of medicinal products' shall mean 
all activities consisting of 
procuring, holding, supplying, 
importing or exporting medicinal 
products. 
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Directive, the definition of 
'medicinal product' set out in 
Article 1 of Council Directive 
65/65/EEC1 shall apply. In 
addition 'wholesale distribution 
of medicinal products' shall 
mean all activities consisting 
of procuring, holding, 
supplying, importing or 
exporting medicinal products 
undertaken with manufacturers, 
importers or other wholesale 
distributors or with pharmacists 
or persons expressly authorized 
to dispense medicinal products 
to the public. 
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Commission text Amendments 
Amendment No. 2 
Art i c 1 e 3 (1) 
1. Member States shall take all 
appropriate measures to ensure 
that the distribution of 
medicinal products is subject to 
the possession of an 
authorization to engage in 
activity as a wholesaler in 
medicinal products. 
1. Member States shall take all 
appropriate measures to ensure 
that the distribution of 
medicinal products is subject to 
the possession of an 
authorization to engage in 
activity as a wholesaler in 
medicinal products, except where 
the distributer is the holder of 
the marketing authorization for 
the medicinal product being 
distributed. 
Amendment No. 3 
Article 3(2} 
2. Pharmacists and persons 
expressly authorized to supply 
medicinal products to the public 
shall be exempt from obtaining 
the authorization referred to in 
paragraph 1, provided that they 
do not engage, principally or 
secondari 1 y, in any activity as 
wholesaler of medicinal 
products. 
2. Pharmacists and persons 
expressly authorized to dispense 
medicinal products to the public 
shall not be obliged to obtain 
the authorization referred to in 
paragraph 1, provided that they 
do not engage, principally or 
secondarily, in any activity as 
wholesaler of medicinal 
products. 
The following shall, for this 
purpose, not be classified as 
wholesale distribution 
activities: obtaining medicinal 
products from the manufacturers, 
importers or wholesale 
distributors for supply to the 
public and returning medicinal 
products acquired from them. 
Amendment No. 4 
Article S(a} 
(a} they must have suitable and 
adequate premises, such as to 
ensure good conservation of the 
medicinal products warehoused; 
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Co11111ission text Amendments 
Amendment No. 5 
Article 6, first line 
Holders of the authorization 
referred to in Article 3(1) shall be 
required: 
Holders of the authorization 
referred to in Article 3(1) shall be 
obliged: 
Amendment No. 6 
Article 6(b) 
(b) to obtain medicinal products 
on 1 y from persons who are 
themselves in possession of the 
authorization referred to in 
Article 3(1) or who are exempt 
from obtaining this 
authorization under the terms of 
Article 3(2); 
(b) to obtain medicinal products 
on 1 y from persons who are 
themselves in possession of ~ 
manufacturing authorization or 
the authorization referred to in 
Article 3(1) or who are exempt 
from obtaining this 
authorization under the terms of 
Article 3(2); 
Amendment No. 7 
Article 6(c) 
(c) to supply medicinal products 
only to persons who are 
themselves in possession of the 
authorization referred to in 
Article 3(1) or who are exempt 
from obtaining this 
authorization under the terms of 
Article 3(2); 
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only to persons who are 
themselves in possession of the 
authorization referred to in 
Article 3(1) or who are exempt 
from obtaining this 
authorization under the terms of 
Article 3(2), or to other 
persons or entities authorized 
to dispense medicinal products 
to the public. 
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CONCLUSION 
The three proposals for directives are aimed at rationalizing the 
distribution of medicinal products for human use in order to facilitate their 
circulation in conditions offering the highest possible security to the 
patient. 
They are consequently in line with the objective of creating a large unified 
market in a sector which has hitherto been relatively compartmentalized. 
Proposal concerning the wholesale distribution of medicinal produc~~ for 
human use 
The completion of the internal market by 1992 will lead to an increase in the 
cross-frontier movement of pharmaceuticals. In this context, the proposal for 
a directive on the wholesale distribution of medicinal products for human use 
lays down the arrangements governing the issue of specific authorizations for 
wholesale distribution in the Community. 
The proposal is to be welcomed, but there is a need to ensure, in the 
interests of both patients and manufacturers, that all the necessary 
guarantees are present in respect of storage, preservation and handling. 
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Dear Mr Collins, 
0 P I N I 0 N 
of the Committee on Budgets 
on the proposals for Council Directives 
on the rational use of medicinal products 
(COM(89) 607 final) 
At its meeting of 1 June 1990 the Commit tee on Budgets considered the above 
subject. 
After considering the proposal itself and the financial implications thereof, 
the Committee on Budgets decided to deliver a favourable opinion. 
Yours sincerely, 
(sgd) Thomas von der VRING 
The following were present: von der Vring, chairman; Arias Canele, Boge, 
Colajanni, Colom 1 Naval, Elles, Kellelt-Bowman, langes, Lo Giudice, McCarlln 
(for Forte), M1randa da Silva, Pasty, Theato, Tomlinson and Wynn . 
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